Bouchaud 2000.

Methods	Randomized controlled trial Length of follow up: 35 d Generation of allocation sequence: unclear Allocation concealment: unclear Blinding: none Inclusion of all randomized participants in the final analysis: 41 analysed/48 randomized (85%)
Participants	Number enrolled: 48 Age range: 15 to 65 years Gender: male and female Inclusion criteria: > 16 years old; had malaria from a short stay in an endemic country; non‐immune individual; parasitaemia between 1000 and 100,000 parasites/µL Exclusion criteria: severe malaria; prolonged QTc interval (above 0.44 s); presence of mixed infections with other Plasmodium species; presence of concomitant disease; inability to take oral treatment; history of syncope; pregnancy; breastfeeding mother; weighed < 40 kg; resided in an endemic area for the previous year
Interventions	1. Atovaquone‐proguanil (4 x 250 mg atovaquone and 4 x 100 mg proguanil as single daily dose for 3 d) 2. Halofantrine (total of 1500 mg in 3 doses of 500 mg 6 h apart)
Outcomes	1. 28‐d cure rate 2. Parasite clearance time 3. Fever clearance
Notes	Location: France Drug resistance: difficult to say as malaria was imported